Biodexa Pharmaceticals (BDRX) - Total Assets
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) holds total assets worth $18.15 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biodexa Pharmaceticals - Total Assets Trend (2012–2025)
This chart illustrates how Biodexa Pharmaceticals's total assets have evolved over time, based on quarterly financial data. Also see market value of Biodexa Pharmaceticals for the company's overall valuation and market capitalisation.
Biodexa Pharmaceticals - Asset Composition Analysis
Current Asset Composition (December 2025)
Biodexa Pharmaceticals's total assets of $18.15 Million consist of 68.5% current assets and 31.6% non-current assets. Review debt load of Biodexa Pharmaceticals to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.9% |
| Accounts Receivable | $221.61K | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.64 Million | 31.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Biodexa Pharmaceticals's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Biodexa Pharmaceticals (BDRX) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biodexa Pharmaceticals's current assets represent 68.5% of total assets in 2025, an increase from 49.4% in 2012.
- Cash Position: Cash and equivalents constituted 46.9% of total assets in 2025, up from 6.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 31.1% of total assets.
Biodexa Pharmaceticals Competitors by Total Assets
Key competitors of Biodexa Pharmaceticals based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Biodexa Pharmaceticals - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.03 | 1.75 | 3.10 |
| Quick Ratio | 2.03 | 1.75 | 3.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.30 Million | $3.78 Million | $6.29 Million |
Biodexa Pharmaceticals - Advanced Valuation Insights
This section examines the relationship between Biodexa Pharmaceticals's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.18 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 22.8% |
| Total Assets | $18.15 Million |
| Market Capitalization | $726.11K USD |
Valuation Analysis
Below Book Valuation: The market values Biodexa Pharmaceticals's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biodexa Pharmaceticals's assets grew by 22.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual total assets of Biodexa Pharmaceticals from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $18.15 Million | +22.78% |
| 2024-12-31 | $14.78 Million | +40.20% |
| 2023-12-31 | $10.54 Million | +90.81% |
| 2022-12-31 | $5.53 Million | -57.21% |
| 2021-12-31 | $12.91 Million | +31.54% |
| 2020-12-31 | $9.82 Million | -68.22% |
| 2019-12-31 | $30.89 Million | +51.12% |
| 2018-12-31 | $20.44 Million | -58.47% |
| 2017-12-31 | $49.22 Million | -13.17% |
| 2016-12-31 | $56.69 Million | -11.48% |
| 2015-12-31 | $64.04 Million | +37.24% |
| 2014-12-31 | $46.66 Million | +801.87% |
| 2013-12-31 | $5.17 Million | +43.31% |
| 2012-12-31 | $3.61 Million | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more